DermBiont: Funding, Investors & Team (Sep 2026)
DermBiont is a biotech firm focused on creating skin microbiome treatments for the prevention and treatment of skin disorders. This company operates at the junction of two dynamic fields: dermatology and the microbiome. They utilize naturally existing microbes found on the human skin, which have evolved over a vast period to combat harmful microorganisms like fungi, bacteria, and viruses. Established in 2017, DermBiont is based in Boston, Massachusetts, with an additional office in Emeryville, California.
DermBiont has raised $43.2M across 4 funding rounds on record, the most recent a Series B of $35.2M announced in Oct 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DermBiont Company Profile and Key Stats
Latest funding round on record: Oct 2023.
DermBiont Funding Rounds
DermBiont raised $800k in an undisclosed round announced in Jan 2022.
8 months later, a Debt Financing of $2.5M was announced in Sep 2022.
6 months later, an undisclosed round of $4.7M was announced in Mar 2023.
7 months later, a Series B of $35.2M was announced in Oct 2023.
DermBiont Founders and Leadership Team
Contact details for the DermBiont team: 1 of 3 have an email address on file.
Start 14-day free trial →DermBiont Funding Compared to Other Biotechnology Startups
DermBiont's latest round of $35.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DermBiont in Biotechnology and Boston
Companies Similar to DermBiont
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
DermBiont Funding FAQs
What does DermBiont do?
DermBiont is a biotech firm focused on creating skin microbiome treatments for the prevention and treatment of skin disorders. This company operates at the junction of two dynamic fields: dermatology and the microbiome. They utilize naturally existing microbes found on the human skin, which have evolved over a vast period to combat harmful microorganisms like fungi, bacteria, and viruses. Established in 2017, DermBiont is based in Boston, Massachusetts, with an additional office in Emeryville, California.
How much funding has DermBiont raised?
DermBiont has raised $43.2M across 4 rounds on record. The most recent is a Series B of $35.2M announced in Oct 2023.
When did DermBiont last raise funding?
DermBiont's most recent funding round on record is a Series B of $35.2M, announced in Oct 2023.
Who founded DermBiont?
FundedIQ lists Nichola Eliovits (Founder), Robert Brucker (Founder) at DermBiont.
Who is the CEO of DermBiont?
Karl Beutner is listed as CEO at DermBiont.
Where is DermBiont headquartered?
DermBiont is based in Boston, Massachusetts, United States.
How many employees does DermBiont have?
DermBiont is in the 11-50 employee band.
How does DermBiont's funding compare to other Biotechnology startups?
DermBiont's latest round of $35.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's DermBiont Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DermBiont is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.